STOCK TITAN

Seelos Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

NEW YORK, April 19, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 2021 RBC Capital Markets Global Healthcare Conference, May 18-20, 2021.

Raj Mehra, Ph.D., Chairman and CEO, will present on Tuesday, May 18th at 4:50pm ET and host 1x1 meetings on May 18th and 19th.

For more information and to register for the webcast: 2021 RBC Capital Markets Global Healthcare Conference

About Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson's disease, other psychiatric and movement disorders plus orphan diseases.

For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.

Contact Information:
Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Avenue
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com 
https://seelostherapeutics.com/ 
https://twitter.com/seelostx 
https://www.linkedin.com/company/seelos

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/seelos-therapeutics-to-participate-in-the-2021-rbc-capital-markets-global-healthcare-conference-301270722.html

SOURCE Seelos Therapeutics, Inc.

Seelos Therapeutics, Inc.

NASDAQ:SEEL

SEEL Rankings

SEEL Latest News

SEEL Stock Data

2.89M
13.40M
2%
21.66%
5.31%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
NEW YORK

About SEEL

seelos therapeutics, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. the company's lead programs are sls-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorder and post-traumatic stress disorder; sls-005, a protein stabilizer for the treatment of sanfilippo syndrome; and sls-006, a partial dopamine agonist for the treatment of patients with parkinson's disease (pd). its preclinical programs include sls-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with pd; sls-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; sls-004 for the treatment of pd; sls-010, an oral histamine h3a receptor antagonist for narcolepsy a